7 research outputs found
ΠΠ°ΡΠ°ΠΎΠΊΡΠΎΠ½Π°Π·Π°: ΡΠ½ΠΈΠ²Π΅ΡΡΠ°Π»ΡΠ½ΡΠΉ ΡΠ°ΠΊΡΠΎΡ Π°Π½ΡΠΈΠΎΠΊΡΠΈΠ΄Π°Π½ΡΠ½ΠΎΠΉ Π·Π°ΡΠΈΡΡ ΠΎΡΠ³Π°Π½ΠΈΠ·ΠΌΠ° ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°
The paraoxonase (PON) gene family includes three members: PON1, PON2, and PON3 aligned in tandem on chromosome 7 in humans. All PON proteins share considerable structural homology and have the capacity to protect cells from oxidative stress; therefore, they have been implicated in the pathogenesis of several inflammatory diseases, particularly atherosclerosis. Increased production of reactive oxygen species as a result of decreased activities of mitochondrial electron transport chain complexes plays a role in the development of many inflammatory diseases, including atherosclerosis. PON1 and PON3 proteins can be detected in plasma and reside in the high-density lipoprotein fraction and protect against oxidative stress by hydrolyzing certain oxidized lipids in lipoproteins, macrophages, and atherosclerotic lesions. Paraoxonase 2 (PON2) possesses antiatherogenic properties and is associated with lower ROS levels. PON2 is involved in the antioxidative and anti-inflammatory response in intestinal epithelial cells. In contrast to PON1 and PON3, PON2 is cell-associated and is not found in plasma. It is widely expressed in a variety of tissues, including the kidney, and protects against cellular oxidative stress. Overexpression of PON2 reduces oxidative status, prevents apoptosis in vascular endothelial cells, and inhibits cell-mediated low density lipoprotein oxidation. PON2 also inhibits the development of atherosclerosis, via mechanisms involving the reduction of oxidative stress. In this review we explore the physiological roles of PON in disease development and modulation of PONs by infective (bacterial, viral) agents.ΠΠ°ΡΠ°ΠΎΠΊΡΠΎΠ½Π°Π·Ρ β ΡΡΠΎ ΡΠ΅ΠΌΠ΅ΠΉΡΡΠ²ΠΎ ΡΠ΅ΡΠΌΠ΅Π½ΡΠΎΠ², ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π½ΠΎΠ΅ PON1, PON2 ΠΈ PON3, ΠΊΠΎΡΠΎΡΡΠ΅ ΠΎΠ±Π»Π°Π΄Π°ΡΡ ΡΠΈΡΠΎΠΊΠΎΠΉ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΡΡ ΠΈ ΠΊΠ°ΡΠ°Π»ΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ½ΠΈΠ²Π΅ΡΡΠ°Π»ΡΠ½ΠΎΡΡΡΡ. PON1 ΠΈ PON3 ΡΠΈΡΠΊΡΠ»ΠΈΡΡΡΡ Π² ΠΏΠ»Π°Π·ΠΌΠ΅ Π² ΡΠΎΡΡΠΎΡΠ½ΠΈΠΈ, ΡΠ²ΡΠ·Π°Π½Π½ΠΎΠΌ Ρ Π»ΠΈΠΏΠΎΠΏΡΠΎΡΠ΅ΠΈΠ½Π°ΠΌΠΈ Π²ΡΡΠΎΠΊΠΎΠΉ ΠΏΠ»ΠΎΡΠ½ΠΎΡΡΠΈ, ΠΏΡΠ΅Π΄ΠΎΡΠ²ΡΠ°ΡΠ°ΡΡ ΠΎΠΊΠΈΡΠ»Π΅Π½ΠΈΠ΅ Π»ΠΈΠΏΡΠΎΠΏΡΠΎΡΠ΅ΠΈΠ½ΠΎΠ², ΡΠΌΠ΅Π½ΡΡΠ°ΡΡ ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠ΅ Π»ΠΈΠΏΠΈΠ΄Π½ΡΡ
ΠΏΠ΅ΡΠΎΠΊΡΠΈΠ΄ΠΎΠ² ΠΈ ΡΠ½ΠΈΠΆΠ°ΡΡ ΡΠΈΡΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ Π°ΡΠ΅ΡΠΎΡΠΊΠ»Π΅ΡΠΎΠ·Π°. PON2 ΡΠ²Π»ΡΠ΅ΡΡΡ Π²Π½ΡΡΡΠΈΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌ ΡΠ΅ΡΠΌΠ΅Π½ΡΠΎΠΌ ΠΈ Π½Π΅ ΠΎΠ±Π½Π°ΡΡΠΆΠΈΠ²Π°Π΅ΡΡΡ Π² ΠΏΠ»Π°Π·ΠΌΠ΅. Β PON2 ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Π° Π²ΠΎ ΠΌΠ½ΠΎΠ³ΠΈΡ
ΡΠΊΠ°Π½ΡΡ
ΠΎΡΠ³Π°Π½ΠΈΠ·ΠΌΠ°, Π²ΠΊΠ»ΡΡΠ°Ρ ΠΏΠ΅ΡΠ΅Π½Ρ, Π»Π΅Π³ΠΊΠΈΠ΅, ΡΡΠ°Ρ
Π΅Ρ, ΠΏΠΎΡΠΊΠΈ, ΡΠ΅ΡΠ΄ΡΠ΅, ΠΏΠΎΠ΄ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠ½ΡΡ ΠΆΠ΅Π»Π΅Π·Ρ, ΡΠΎΠ½ΠΊΠΈΠΉ ΠΊΠΈΡΠ΅ΡΠ½ΠΈΠΊ, ΠΌΡΡΡΡ, ΡΠ΅ΠΌΠ΅Π½Π½ΠΈΠΊΠΈ ΠΈ ΡΠ½Π΄ΠΎΡΠ΅Π»ΠΈΠ°Π»ΡΠ½ΡΠ΅ ΠΊΠ»Π΅ΡΠΊΠΈ. PON2 ΡΠ°ΠΊΠΆΠ΅ ΠΏΡΠΈΡΡΡΡΡΠ²ΡΠ΅Ρ Π² Π΄ΠΎΡΠ°ΠΌΠΈΠ½Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΠ±Π»Π°ΡΡΡΡ
Π³ΠΎΠ»ΠΎΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π° ΠΈ Π² Π°ΡΡΡΠΎΡΠΈΡΠ°Ρ
. ΠΠ° ΡΡΠ±ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΌ ΡΡΠΎΠ²Π½Π΅, PON2 Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΡΠ΅ΡΡΡ Π² ΠΌΠΈΡΠΎΡ
ΠΎΠ½Π΄ΡΠΈΡΡ
, Π³Π΄Π΅ ΠΏΡΠ΅Π΄ΠΎΡΠ²ΡΠ°ΡΠ°Π΅Ρ Π½Π°ΠΊΠΎΠΏΠ»Π΅Π½ΠΈΠ΅ ΡΡΠΈΠ³Π»ΠΈΡΠ΅ΡΠΈΠ΄ΠΎΠ² ΠΈ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ ΠΎΠΊΠΈΡΠ»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΡΡΡΠ΅ΡΡΠ°. PON3 - ΠΏΠΎΡΠ»Π΅Π΄Π½ΡΡ ΠΈΠ· ΠΎΡΠΊΡΡΡΡΡ
ΠΏΠ°ΡΠ°ΠΎΠΊΡΠΎΠ½Π°Π· ΠΎΠ±Π»Π°Π΄Π°Π΅Ρ Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΠΉ Π°Π½ΡΠΈΠΊΡΠΈΠ΄Π°Π½ΡΠ½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ. PON3 ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Π° Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
ΠΊΠΎΠΆΠΈ, ΡΠ»ΡΠ½Π½ΡΡ
ΠΆΠ΅Π»Π΅Π·Π°Ρ
, ΠΆΠ΅Π»Π΅Π·ΠΈΡΡΠΎΠΌ ΡΠΏΠΈΡΠ΅Π»ΠΈΠΈ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ°, ΠΊΠΈΡΠ΅ΡΠ½ΠΈΠΊΠ°, ΡΠ½Π΄ΠΎΠΌΠ΅ΡΡΠΈΠΈ, Π³Π΅ΠΏΠ°ΡΠΎΡΠΈΡΠ°Ρ
,Β ΠΊΠ»Π΅ΡΠΊΠ°Ρ
ΠΏΠΎΠ΄ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, ΡΠ΅ΡΠ΄ΡΠ΅, ΠΆΠΈΡΠΎΠ²ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ ΠΈ Π² Π»Π΅Π³ΠΎΡΠ½ΠΎΠΌ ΡΠΏΠΈΡΠ΅Π»ΠΈΠΈ. PON3 Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ ΠΈΠ·ΡΡΠ΅Π½Π°, Π½ΠΎ Π΄ΠΎΠΊΠ°Π·Π°Π½ΠΎ Π΅Π΅ Π°Π½ΡΠΈΠΎΠΊΡΠΈΠ΄Π°Π½ΡΠ½ΠΎΠ΅, ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ΅ ΠΈ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΌΠΈΠΊΡΠΎΠ±Π½ΠΎΠ΅ Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅Β Π·Π° ΡΡΠ΅Ρ Π±Π»ΠΎΠΊΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΊΠ²ΠΎΡΡΠΌ-Π·Π°Π²ΠΈΡΠΈΠΌΡΡ
ΡΠΈΡΡΠ΅ΠΌ Π±Π°ΠΊΡΠ΅ΡΠΈΠΉ. ΠΠ·Π±ΡΡΠΎΡΠ½Π°Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ PON3 ΡΠΌΠ΅Π½ΡΡΠ°Π΅Ρ ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠ΅ Π°ΡΠ΅ΡΠΎΡΠΊΠ»Π΅ΡΠΎΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π±Π»ΡΡΠ΅ΠΊ ΠΈ ΠΏΡΠ΅ΠΏΡΡΡΡΠ²ΡΠ΅Ρ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΎΠΆΠΈΡΠ΅Π½ΠΈΡ, ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ PON3 ΡΠ²Π΅Π»ΠΈΡΠΈΠ²Π°Π΅ΡΡΡ ΠΏΡΠΈ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΡ
, ΠΏΠΎΠ²ΡΡΠ°Ρ ΡΠΎΠΏΡΠΎΡΠΈΠ²Π»Π΅Π½ΠΈΠ΅ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ ΠΊ ΠΎΠΊΡΠΈΠ΄Π°ΡΠΈΠ²Π½ΠΎΠΌΡ ΡΡΡΠ΅ΡΡΡ ΠΈ Π°ΠΏΠΎΠΏΡΠΎΠ·Ρ.
Π ΠΎΠ±Π·ΠΎΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π° ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ ΠΎ ΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΎΠ΄ΠΈ ΠΏΠ°ΡΠ°ΠΎΠΊΡΠΎΠ½Π°Π·, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΈΡ
ΡΡΠ°ΡΡΠΈΠΈ Π² ΡΠ°Π·Π²ΠΈΡΠΈΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ, Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Ρ ΠΎΠΊΠΈΡΠ»ΠΈΡΠ΅Π»ΡΠ½ΡΠΌ ΡΡΡΠ΅ΡΡΠΎΠΌ (Π°ΡΠ΅ΡΠΎΡΠΊΠ»Π΅ΡΠΎΠ·, ΡΠ½Π΄ΠΎΠΌΠ΅ΡΡΠΈΠΎΠ·, Π±ΠΎΠ»Π΅Π·Π½Ρ ΠΠ°ΡΠΊΠΈΠ½ΡΠΎΠ½Π°, ΡΠΈΡΡΠΎΠ· ΠΏΠ΅ΡΠ΅Π½ΠΈ, Π±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΠ΅ ΠΈ Π²ΠΈΡΡΡΠ½ΡΠ΅ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΠΈ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΠ΅ ΠΏΡΠΎΡΠ΅ΡΡΡ)
Paraoxonase: The universal factor of antioxidant defense in Human Body
The paraoxonase (PON) gene family includes three members: PON1, PON2, and PON3 aligned in tandem on chromosome 7 in humans. All PON proteins share considerable structural homology and have the capacity to protect cells from oxidative stress; therefore, they have been implicated in the pathogenesis of several inflammatory diseases, particularly atherosclerosis. Increased production of reactive oxygen species as a result of decreased activities of mitochondrial electron transport chain complexes plays a role in the development of many inflammatory diseases, including atherosclerosis. PON1 and PON3 proteins can be detected in plasma and reside in the high-density lipoprotein fraction and protect against oxidative stress by hydrolyzing certain oxidized lipids in lipoproteins, macrophages, and atherosclerotic lesions. Paraoxonase 2 (PON2) possesses antiatherogenic properties and is associated with lower ROS levels. PON2 is involved in the antioxidative and anti-inflammatory response in intestinal epithelial cells. In contrast to PON1 and PON3, PON2 is cell-associated and is not found in plasma. It is widely expressed in a variety of tissues, including the kidney, and protects against cellular oxidative stress. Overexpression of PON2 reduces oxidative status, prevents apoptosis in vascular endothelial cells, and inhibits cell-mediated low density lipoprotein oxidation. PON2 also inhibits the development of atherosclerosis, via mechanisms involving the reduction of oxidative stress. In this review we explore the physiological roles of PON in disease development and modulation of PONs by infective (bacterial, viral) agents
Paraoxonase: The universal factor of antioxidant defense in Human Body
The paraoxonase (PON) gene family includes three members: PON1, PON2, and PON3 aligned in tandem on chromosome 7 in humans. All PON proteins share considerable structural homology and have the capacity to protect cells from oxidative stress; therefore, they have been implicated in the pathogenesis of several inflammatory diseases, particularly atherosclerosis. Increased production of reactive oxygen species as a result of decreased activities of mitochondrial electron transport chain complexes plays a role in the development of many inflammatory diseases, including atherosclerosis. PON1 and PON3 proteins can be detected in plasma and reside in the high-density lipoprotein fraction and protect against oxidative stress by hydrolyzing certain oxidized lipids in lipoproteins, macrophages, and atherosclerotic lesions. Paraoxonase 2 (PON2) possesses antiatherogenic properties and is associated with lower ROS levels. PON2 is involved in the antioxidative and anti-inflammatory response in intestinal epithelial cells. In contrast to PON1 and PON3, PON2 is cell-associated and is not found in plasma. It is widely expressed in a variety of tissues, including the kidney, and protects against cellular oxidative stress. Overexpression of PON2 reduces oxidative status, prevents apoptosis in vascular endothelial cells, and inhibits cell-mediated low density lipoprotein oxidation. PON2 also inhibits the development of atherosclerosis, via mechanisms involving the reduction of oxidative stress. In this review we explore the physiological roles of PON in disease development and modulation of PONs by infective (bacterial, viral) agents
Placental vasculogenesis and angiogenesis in women undergoing chemotherapy
Yu.E. Dobrokhotova1, E.I. Borovkova1, A.M. Arutyunyan1, S.Zh. Danelyan2, E.M. Malysheva2, N.V. Zharkov2,3, T.N. Aksenova2
1 Pirogov Russian National Research Medical University, Moscow, Russian Federation
2City Clinical Hospital No. 40, Moscow, Russian Federation
3 I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
Aim: to study placental vasculogenesis and angiogenesis in women receiving chemotherapy.
Patients and Methods: placental structure was examined in 57 pregnant women aged 22β38 years who were subdivided into 3 groups, i.e., women with malignancies receiving or not receiving chemotherapy and healthy controls. The slices of the central part of placentas collected after childbirth were examined. Immunohistochemistry (IHC) was performed after standard histology. IHC intensity was assessed for CD31 and CD34. In addition to IHC intensity, the number of positive cells per field of view was calculated for VEGF, VEGFR1, and VEGFR2. Mean counts of positive cells separately for epithelial and stromal cells were calculated for eNOS.
Results: in the control group, the maturity of the placental villous tree matched the gestational age. Meanwhile, in 100% of pregnant women with malignancies receiving chemotherapy and in 46.8% of pregnant women with malignancies not receiving chemot herapy, the maturity of the placental villous tree was 2β4 weeks behind the gestational age. IHC revealed no significant differences in the placental concentrations of CD31, CD39, eNOS, VEGF, VEGFR1, and VEGFR2 between women with malignancies not receiving chemotherapy and the controls. In women receiving chemotherapy, IHC intensity and the number of positive cells were twice as high as in the control group. The activity of VEGFR1 and VEGFR2 was 11 times higher and 1.4 times higher, respectively, than in the control group. The mean number of cells expressing VEGFR1 and VEGFR2 per field of view increased by 1.5 times and 1.7 times, respectively. In addition, 1.6-fold reduction in CD31 level and 1.3-fold reduction in CD34 level as well as 1.4-fold increase in epithelial Π΅NOS level and 1.3-fold increase in stromal eNOS level were revealed.
Conclusions: our findings on IHC distribution of the expression of VEGF and its recep-tors in the placental tissue of pregnant women undergoing cytostatic chemotherapy in part illus-trate the processes of the compensation and impaired functioning of the mother-placenta-fetus system in pre-placental hypoxia.
Keywords: angiogenesis, vasculogenesis, vascular growth factor, chemotherapy, hypoxia, placental insufficiency.
For citation: Yu.E. Dobrokhotova, Borovkova E.I., Arutyunyan A.M., Danelyan S.Zh. et al. Placental vasculogenesis and angiogenesis in women undergoing chemotherapy. Russian Journal of Woman and Child Health. 2021;4(1):23β30. DOI: 10.32364/2618-8430-2021-4-1-23-30.
</p
ΠΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΡ ΡΠ°Π±ΠΎΡΠΈΡ ΠΏΡΠΎΡΠ΅ΡΡΠΎΠ² ΠΏΠΎ ΡΠ΅ΠΊΡΡΡΠΈΠ½Π³Ρ Π΄ΠΎΠ½ΠΎΡΠΎΠ² ΠΈ Π·Π°Π³ΠΎΡΠΎΠ²ΠΊΠ΅ ΡΠ΅ΠΊΠΎΠ½Π²Π°Π»Π΅ΡΡΠ΅Π½ΡΠ½ΠΎΠΉ ΠΏΠ»Π°Π·ΠΌΡ Π² ΠΏΠ΅ΡΠΈΠΎΠ΄ ΠΏΠ°Π½Π΄Π΅ΠΌΠΈΠΈ COVID-19
Background. The pandemic of the new coronavirus infection has challenged the medical community for quickly finding and implementing effective methods of treatment. In the absence of a vaccine or specific therapy with proven effectiveness, the usage of convalescent plasma can be the one of perspective methods. An important aspect of this technology is the efficient and safe preparation of convalescent plasma. To date, in the world literature there are practically no publications about donor recruitment and the specifics of the preparation of convalescent plasma.
Purpose of the research. Presentation of the experience of organizing a workflow for recruiting donors and stockpiling of convalescent plasma with a high titer of virus-neutralizing antibodies to SARS-CoV-2.
Methods. The analysis of the work of the Blood Service of the Moscow Department of Health for stockpiling of COVID-19 convalescent plasma has been executed. In total it has been stockpiled 1240 doses. The normative documentation has been developed by a working group on the basis of the current federal legislation of Russian federation and been approved by the Moscow Department of Health. The titer of neutralizing antibodies (VNA) has been determined as the basic method for assessing the immunological viability of convalescent plasma. The main characteristics of donors, the characteristics of the disease course, the results of preliminary testing for the presence of specific antibodies by ELISA and CLIA methods has been compared with VNA titers in the stockpiled convalescent plasma.
Results. Due to a Moscow Health Departments order No. 325 dated 01.04.2020 (a basic local regulatory document) it has been developed a regulation for the stockpiling, examination, storage, safety and transfering of fresh frozen pathogen-reduced plasma of COVID-19 convalescent donors to medical organizations of the Moscow Health Department. For arranging an interaction with donors it has been created a call-center. For effective preliminary selection, it has been formed a donor characteristics list, which has been combined with screening of specific antibodies by ELISA and CLIA methods.
Conclusions. Developed a system of recruiting donors and procurement process of convalescent plasma for treatment Π‘OVID-19, which includes the necessary regulations, algorithms for the selection and recruitment of donors, the registry of donors and recipients, algorithms, efficiency and safety of convalescent plasma.ΠΠ±ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠ΅. ΠΠ°Π½Π΄Π΅ΠΌΠΈΡ Π½ΠΎΠ²ΠΎΠΉ ΠΊΠΎΡΠΎΠ½Π°Π²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΠΏΠΎΡΡΠ°Π²ΠΈΠ»Π° ΠΏΠ΅ΡΠ΅Π΄ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΠΌ ΡΠΎΠΎΠ±ΡΠ΅ΡΡΠ²ΠΎΠΌ Π·Π°Π΄Π°ΡΡ Π±ΡΡΡΡΠΎΠ³ΠΎ ΠΏΠΎΠΈΡΠΊΠ° ΠΈ Π²Π½Π΅Π΄ΡΠ΅Π½ΠΈΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊ Π»Π΅ΡΠ΅Π½ΠΈΡ. Π ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΠΎΡΡΡΡΡΡΠ²ΠΈΡ Π²Π°ΠΊΡΠΈΠ½Ρ ΠΈ ΡΡΠ΅Π΄ΡΡΠ² ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Ρ Π΄ΠΎΠΊΠ°Π·Π°Π½Π½ΠΎΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΎΠ΄Π½ΠΎΠΉ ΠΈΠ· ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊ ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°Π΅ΡΡΡ ΡΡΠ°Π½ΡΡΡΠ·ΠΈΡ ΡΠ΅ΠΊΠΎΠ½Π²Π°Π»Π΅ΡΡΠ΅Π½ΡΠ½ΠΎΠΉ ΠΏΠ»Π°Π·ΠΌΡ (Π Π). ΠΠ°ΠΆΠ½ΡΠΌ Π°ΡΠΏΠ΅ΠΊΡΠΎΠΌ Π΄Π°Π½Π½ΠΎΠΉ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ ΡΠ²Π»ΡΠ΅ΡΡΡ Π·Π°Π³ΠΎΡΠΎΠ²ΠΊΠ° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠ°. ΠΠ° ΡΠ΅Π³ΠΎΠ΄Π½ΡΡΠ½ΠΈΠΉ Π΄Π΅Π½Ρ ΠΏΡΠ±Π»ΠΈΠΊΠ°ΡΠΈΠΈ ΠΏΠΎ ΡΠ΅ΠΊΡΡΡΠΈΠ½Π³Ρ Π΄ΠΎΠ½ΠΎΡΠΎΠ² ΠΈ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΡΡ
Π·Π°Π³ΠΎΡΠΎΠ²ΠΊΠΈ Π Π Π² ΠΌΠΈΡΠΎΠ²ΠΎΠΉ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΠ΅ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ ΠΎΡΡΡΡΡΡΠ²ΡΡΡ.
Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΠ½Π°Π»ΠΈΠ· ΠΎΠΏΡΡΠ° ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠΈ ΡΠ°Π±ΠΎΡΠ΅Π³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ° ΠΏΠΎ ΠΏΡΠΈΠ²Π»Π΅ΡΠ΅Π½ΠΈΡ Π΄ΠΎΠ½ΠΎΡΠΎΠ² ΠΈ Π·Π°Π³ΠΎΡΠΎΠ²ΠΊΠ΅ Π Π Ρ Π²ΡΡΠΎΠΊΠΈΠΌ ΡΠΈΡΡΠΎΠΌ Π²ΠΈΡΡΡΠ½Π΅ΠΉΡΡΠ°Π»ΠΈΠ·ΡΡΡΠΈΡ
Π°Π½ΡΠΈΡΠ΅Π» ΠΊ SARS-CoV-2.
ΠΠ΅ΡΠΎΠ΄Ρ. ΠΡΠΎΠ²Π΅Π΄Π΅Π½ Π°Π½Π°Π»ΠΈΠ· ΡΠ°Π±ΠΎΡΡ Π‘Π»ΡΠΆΠ±Ρ ΠΊΡΠΎΠ²ΠΈ ΠΠ΅ΠΏΠ°ΡΡΠ°ΠΌΠ΅Π½ΡΠ° Π·Π΄ΡΠ°Π²ΠΎΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΡ Π³. ΠΠΎΡΠΊΠ²Ρ (ΠΠΠ) ΠΏΠΎ Π·Π°Π³ΠΎΡΠΎΠ²ΠΊΠ΅ Π Π COVID-19. ΠΡΠ΅Π³ΠΎ Π·Π°Π³ΠΎΡΠΎΠ²Π»Π΅Π½ΠΎ 1240 Π΄ΠΎΠ·. ΠΠΎΡΠΌΠ°ΡΠΈΠ²Π½Π°Ρ Π΄ΠΎΠΊΡΠΌΠ΅Π½ΡΠ°ΡΠΈΡ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π° ΡΠ°Π±ΠΎΡΠ΅ΠΉ Π³ΡΡΠΏΠΏΠΎΠΉ Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ Π΄Π΅ΠΉΡΡΠ²ΡΡΡΠ΅Π³ΠΎ ΡΠ΅Π΄Π΅ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π·Π°ΠΊΠΎΠ½ΠΎΠ΄Π°ΡΠ΅Π»ΡΡΡΠ²Π° ΠΈ ΡΡΠ²Π΅ΡΠΆΠ΄Π΅Π½Π° ΠΠΠ. ΠΠ°ΠΊ Π±Π°Π·ΠΎΠ²Π°Ρ ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠ° ΠΎΡΠ΅Π½ΠΊΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΎΡΡΠΎΡΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ Π Π, ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ ΡΠΈΡΡ Π²ΠΈΡΡΡΠ½Π΅ΠΉΡΡΠ°Π»ΠΈΠ·ΡΡΡΠΈΡ
Π°Π½ΡΠΈΡΠ΅Π» (ΠΠΠ). ΠΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΡΠΎΠΏΠΎΡΡΠ°Π²Π»Π΅Π½ΠΈΠ΅ ΠΎΡΠ½ΠΎΠ²Π½ΡΡ
Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊ Π΄ΠΎΠ½ΠΎΡΠΎΠ², ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ ΡΠ΅ΡΠ΅Π½ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² ΠΏΡΠ΅Π΄Π²Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π½Π° Π½Π°Π»ΠΈΡΠΈΠ΅ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π°Π½ΡΠΈΡΠ΅Π» ΠΌΠ΅ΡΠΎΠ΄Π°ΠΌΠΈ ΠΠ€Π ΠΈ ΠΠ₯ΠΠ Ρ ΡΠΈΡΡΠ°ΠΌΠΈ ΠΠΠ Π·Π°Π³ΠΎΡΠΎΠ²Π»Π΅Π½Π½ΠΎΠΉ Π Π.
Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π Π°Π±ΠΎΡΠ° ΠΏΠΎ Π·Π°Π³ΠΎΡΠΎΠ²ΠΊΠ΅, ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ, Ρ
ΡΠ°Π½Π΅Π½ΠΈΡ, ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠ΅Π½ΠΈΡ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΠΈ ΠΏΠ΅ΡΠ΅Π΄Π°ΡΠ΅ Π² ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΠ΅ ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠΈ ΠΠΠ ΡΠ²Π΅ΠΆΠ΅Π·Π°ΠΌΠΎΡΠΎΠΆΠ΅Π½Π½ΠΎΠΉ ΠΏΠ°ΡΠΎΠ³Π΅Π½ΡΠ΅Π΄ΡΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΏΠ»Π°Π·ΠΌΡ Π΄ΠΎΠ½ΠΎΡΠΎΠ²-ΡΠ΅ΠΊΠΎΠ½Π²Π°Π»Π΅ΡΡΠ΅Π½ΡΠΎΠ² COVID-19 Π±ΡΠ»Π° ΠΎΡΠ³Π°Π½ΠΈΠ·ΠΎΠ²Π°Π½Π° Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΏΡΠΈΠΊΠ°Π·Π° ΠΠΠ ΠΎΡ 01.04.2020 β 325 ΠΊΠ°ΠΊ Π±Π°Π·ΠΎΠ²ΠΎΠ³ΠΎ Π»ΠΎΠΊΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π½ΠΎΡΠΌΠ°ΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π΄ΠΎΠΊΡΠΌΠ΅Π½ΡΠ°. ΠΠ»Ρ ΠΎΠΏΡΠΈΠΌΠ°Π»ΡΠ½ΠΎΠΉ ΠΊΠΎΠΌΠΌΡΠ½ΠΈΠΊΠ°ΡΠΈΠΈ Ρ ΡΠΎΡΡΠΎΡΠ²ΡΠΈΠΌΠΈΡΡ Π΄ΠΎΠ½ΠΎΡΠ°ΠΌΠΈ ΠΈ ΠΏΡΠΈΠ²Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΠ΅ΠΊΠΎΠ½Π²Π°Π»Π΅ΡΡΠ΅Π½ΡΠΎΠ² ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈΡΡ ΡΠ΅ΡΡΡΡΡ ΠΊΠΎΠ»Π»-ΡΠ΅Π½ΡΡΠ°. ΠΠ»Ρ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΠΏΡΠ΅Π΄Π²Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΎΡΠ±ΠΎΡΠ° Π΄ΠΎΠ½ΠΎΡΠΎΠ² ΠΏΡΠΈΠΌΠ΅Π½ΡΠ»ΠΈΡΡ Π°Π½Π°Π»ΠΈΠ· Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊ Π΄ΠΎΠ½ΠΎΡΠ° (ΠΏΠ»Π°Π·ΠΌΠ° Ρ Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠΈΠΌΠΈ Π·Π½Π°ΡΠ΅Π½ΠΈΡΠΌΠΈ ΡΠΈΡΡΠ° ΠΠΠ ΠΎΠΆΠΈΠ΄Π°Π΅ΠΌΠ° ΠΎΡ Π΄ΠΎΠ½ΠΎΡΠΎΠ²-ΠΌΡΠΆΡΠΈΠ½, ΠΏΠ΅ΡΠ΅Π±ΠΎΠ»Π΅Π²ΡΠΈΡ
Ρ ΠΏΡΠΈΠ·Π½Π°ΠΊΠ°ΠΌΠΈ ΡΠ²Π½ΠΎΠΉ Π²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΏΠ½Π΅Π²ΠΌΠΎΠ½ΠΈΠΈ) ΠΈ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³Π° ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π°Π½ΡΠΈΡΠ΅Π» ΠΌΠ΅ΡΠΎΠ΄Π°ΠΌΠΈ ΠΠ€Π ΠΈ ΠΠ₯ΠΠ.
ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π Π°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π° ΡΠΈΡΡΠ΅ΠΌΠ° ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠ΅Π½ΠΈΡ ΡΠ΅ΠΊΡΡΡΠΈΠ½Π³Π° Π΄ΠΎΠ½ΠΎΡΠΎΠ² ΠΈ ΠΏΡΠΎΡΠ΅ΡΡΠ° Π·Π°Π³ΠΎΡΠΎΠ²ΠΊΠΈ Π Π Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ Π‘OVID-19, Π²ΠΊΠ»ΡΡΠ°ΡΡΠ°Ρ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΡΠ΅ Π½ΠΎΡΠΌΠ°ΡΠΈΠ²Π½ΡΠ΅ Π΄ΠΎΠΊΡΠΌΠ΅Π½ΡΡ, Π°Π»Π³ΠΎΡΠΈΡΠΌΡ ΠΎΡΠ±ΠΎΡΠ° ΠΈ ΠΏΡΠΈΠ²Π»Π΅ΡΠ΅Π½ΠΈΡ Π΄ΠΎΠ½ΠΎΡΠΎΠ², ΡΠ΅Π΅ΡΡΡ Π΄ΠΎΠ½ΠΎΡΠΎΠ² ΠΈ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ², Π°Π»Π³ΠΎΡΠΈΡΠΌΡ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠ΅Π½ΠΈΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ Π Π